Content Preview

CITI EXAMS 2025 QUESTIONS AND ANSWERS A subject in a clinical research trial experiences a serious, unanticipated adverse drug experience. How should the investigator proceed, with respect to the IRB, after the discovery of the adverse event occurrence? - ....ANSWER ...-Report the adverse drug experience in a timely manner, in keeping with the IRB's policies and procedures, using the forms or the mechanism provided by the IRB. How long is an investigator required to keep consent documents, IRB correspondence, and research records? - ....ANSWER ...-For a minimum of three years after completion of the study According to federal regulations, which of the following best describes when expedited review of a new, proposed study may be used by the IRB? - ....ANSWER ...-The study involves no more than minimal risk and meets one of the allowable categories of expedited review specified in federal regulations Amendments involving changes to IRB-approved protocols do NOT need prior IRB approval if: - ....ANSWER ...-The changes must be immediately implemented for the health and well-being of the subject. IRB continuing review of a greater than minimal risk approved protocol that is currently enrolling subjects must: - ....ANSWER ...-Occur at least annually. ...©️ 2025, ALL RIGHTS RESERVED 1